Tagged with R

Pharma Legal Handbook 1. What types of liability are recognized in your jurisdiction? The failure to comply with the Romanian pharma legislation can trigger disciplinary, civil, material, contraventional or criminal liability, depending on the case. Additionally, the competent authorities in various fields can apply fines and other sanctions when the breach is related…

Pharma Legal Handbook 1. What are the basic requirements to obtain patent and trademark protection? As a rule, a patent or a trademark protection can only be obtained by registration with the State Office for Inventions and Trademarks (“OSIM”), based on the specific provisions stipulated by Law no. 84/1998 on trademarks and geographical…

Pharma Legal Handbook 1. Are there proposals for reform or significant change to the healthcare system? The Romanian authorities announced their intention to implement certain changes in the pharmaceutical legislation, including in relation to: the new advertising norms for medical devices, which will bring significant changes in connection with the marketing and advertising…

Pharma Legal Handbook Cannabinoid Drugs 1. Are Cannabinoid Drugs authorized in your country? According to the national catalogue of medicines in Romania published by NAMMD, currently there is one medicinal product authorized for marketing in the country having as active substance cannabidiolum. By law, certain narcotic or psychotropic substances extracted from cannabis, such…

Pharma Legal Handbook 1. What is the definition of Rare Diseases in your country? Regulation (EC) no. 141/2000 on orphan medicinal products (“Regulation no. 141/2000”), which is directly applicable in Romania, specifies that a medicinal product could be designated by the European Medicines Agency as an orphan medicine when: (i) it is intended…

Pharma Legal Handbook 1. Are there any rules or regulations requiring and/or encouraging localization in your country? What is the legal framework defining these localization rules and policies? Romania has a favourable tax regime for companies, which encourages many businesses to set up and to operate subsidiaries in Romania. However, there are no…

Pharma Legal Handbook 1. Are biosimilar medicines considered the same as generic medicines in your country? The biosimilar medicinal products are not considered the same as generic medicinal products, since the Romanian legislation regulates biosimilars and generics in a different manner. As per the local legislation, a biosimilar is a biologic medicinal product…

Japan Japan was once a global leader in life sciences innovation, introducing about a third of the world’s new drugs in the 1980s, but this positioning slipped following decades of economic stagnation compounded by a conservative regulatory regime. However recent regulatory reforms have brought a more positive outlook and sparked a…

France At the end of a turbulent and lengthy process, France’s 2025 health budget has finally been approved. This “imperfect” budget resulting from months of debate in a parliament with no absolute majority does not embrace the more radical cost-cutting measures originally proposed. It does raise funding for hospitals by EUR…

USA The US pharmaceutical industry is scrambling to align with President Donald Trump’s policy agenda, but may not get all it wishes for…   In its first few weeks in power, the emboldened second Trump administration has enacted a scattergun set of executive orders, covering everything from swingeing cuts to the…

Puerto Rico In a rapidly evolving global landscape, medtech manufacturer Copan Industries (part of Copan Group) has strategically chosen Puerto Rico as a key hub for its expansion in the Americas, attracted by the island’s skilled workforce and strong institutional support. As COO Efraín Rodriguez explains, with over $100 million invested, the…

Saudi Arabia Dr Abdulaziz Alswailem, the CEO of the Saudi Authority for Intellectual Property (SAIP), reflects on the country’s growing role in global intellectual property (IP) policy. He highlights Saudi Arabia’s efforts to foster a strong IP ecosystem through national and international collaborations, such as the Riyadh Design Law Treaty, which sets…